The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge

References

• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet. 2007;370(9588):667–675.
   PubMed Web of Science ®Google Scholar
• Association AD. Overcoming therapeutic inertia. cited 2021 Aug 02. https://therapeuticinertia.diabetes.org
   Google Scholar
• Andary R, Fan W, Wong ND. Control of cardiovascular risk factors among US adults with type 2 diabetes with and without cardiovascular disease. Am J Cardiol. 2019;124(4):522–527.
   PubMed Web of Science ®Google Scholar
• Loutradis C, Papadopoulou E, Angeloudi E, et al. The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia. Curr Med Chem. 2020;27(39):6682–6702. PMID: 31663470.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020 Feb 4;9(3):e014908. Epub 2020 Jan 29. PMID: 31992158; PMCID: PMC7033896.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018 Jan 20;7(2):e007165. PMID: 29353233; PMCID: PMC5850151.
   PubMed Web of Science ®Google Scholar
• Teo YH, Teo YN, Syn NL, et al. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021 Feb;10(5):e019463. Epub 2021 Feb 24. PMID: 33625242; PMCID: PMC8174267
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 Diabetes: a meta-analysis. JAMA Cardiol. 2021 Feb;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Gay H, Yu J, Petito L, et al. Abstract 14678: prevalence of SGLT2 inhibitor and GLP-1 receptor agonist prescriptions in patients with comorbid diabetes and cardiovascular disease in an integrated academic health system. Circulation. 2020;142(Suppl_3):A14678–A14678.
   Google Scholar
• Arnold SV, de Lemos JA, Rosenson RS, et al. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019;140(7):618–620.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Sathiyakumar V, Singh A, et al. Prescriber Patterns of SGLT2i after expansions of U.S. food and drug administration labeling. J Am Coll Cardiol. 2018;72(25):3370–3372.
   PubMed Web of Science ®Google Scholar
• Vigersky RA, Fish L, Hogan P, et al. The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab. 2014;99(9):3112–3121.
   PubMed Web of Science ®Google Scholar
• Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. Am Heart J. 2020;224:47–53.
   PubMed Web of Science ®Google Scholar
• Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). Lancet Diabetes Endocrinol. 2021; 2213–8587. https://doi.org/10.1016/S2213-8587(21)00240.
   Google Scholar
• Unnikrishnan R, Mohan V. Newer antidiabetic agents: at what price will they be cost effective? Lancet Diabetes Endocrinol. 2021; 2213–8587. https://doi.org/10.1016/S2213-8587(21)00240.
   Web of Science ®Google Scholar
• Gunawan F, Partridge C, Kosiborod M, et al. SUN-149 cardiologist vs. endocrinologist encounters in patients with T2D and CVD: potential implications for glucose-lowering therapy use and education. J Endocr Soc. 2019;3(Supplement_1):SUN–149.
   Google Scholar
• Maddox Thomas M, Januzzi James L, Allen Larry A, et al. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77(6):772–810.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Fonarow GC, Greene SJ, et al. Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry. JACC Heart Fail. 2020;8(6):469–480.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. SOLOIST-WHF trial investigators. sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021Jan14;384(2):117–128. Epub 2020 Nov 16. PMID: 33200892.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. SCORED investigators. sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021Jan14;384(2):129–139. Epub 2020 Nov 16. PMID: 33200891.
   PubMed Web of Science ®Google Scholar
• Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73–90.
   PubMed Web of Science ®Google Scholar
• Das SR, Everett BM, Birtcher KK, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 Diabetes: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117–1145.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation. 2020;142(23):2205–2215.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Adhikari R, Blaha M. New insights into prescribing of SGLT2 Inhibitors and GLP-1 receptor agonists by cardiologists in 2020: major barriers limiting role. American College of Cardiology Website; Jan 19, 2021 cited 2021 Oct 23. https://www.acc.org/latest-in-cardiology/articles/2021/01/19/14/27/new-insights-into-prescribing-of-sglt2-inhibitors-and-glp-1-receptor-agonists-in-2020
   Google Scholar
• Singhal P, Liu G, Miller S, et al. Clinical practice patterns and attitudes about prescribing sglt2 inhibitors at a single-center academic safety-net hospital. J Am Coll Cardiol. 2021;77(18):1543.
   Web of Science ®Google Scholar
• Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. J Am Coll Cardiol Heart Failure. 2019;7(2):169–172.
   PubMed Web of Science ®Google Scholar
• American College of Cardiology. Succeed in managing cardiovascular risk in diabetes initiative. cited 2021 Oct 23.https://www.acc.org/tools-and-practice-support/quality-programs/cardiovascular-risk-in-diabetes-initiative
   Google Scholar